Crafting claim strategies in animal and human therapeutics

There are varying national eligibility requirements that distinguish between treatments of and diagnostics for animals and humans; it’s just a question of reformatting ‘method of treatment’ claims, write lawyers from Sterne Kessler.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J unit targets former employee over alleged mass data theft

17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.

Americas

Mylan withdraws defence claims against Novo in Wegovy dispute

13 March 2026 A proposed judgment by the rivals would extend the period in which Mylan is barred from obtaining regulatory approval for its generic of the weight-loss injectable.

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

More features

J&J unit targets former employee over alleged mass data theft

HSF Kramer hires patent litigator as partner in Germany

INTA: ‘New normal’ for in-house counsel as budgets fall

Mylan withdraws defence claims against Novo in Wegovy dispute

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

GSK inks licensing deal for liver disease drug

Crafting claim strategies in animal and human therapeutics

More on this story

Editor's picks

Editor's picks

More features